VBI Vaccines Inc.

VBI Vaccines — Corporate Update (November 2020)

8 slides from VBI Vaccines's corporate update, Nov 18, 2020

  1. Slide 1: VBI-2601 (BRII-179): Interim Phase 1b/2a Data

    NW, Mb \ MW Ut, VBI VACCINES TTS VBI-2601 (BRII-179) : Interim Phase 1b/2a Data Jeff Baxter, CEO, and David E. Anderson, Ph.D., CSO NASDAQ: VBIV NOVEMBER 18 2020

  2. Slide 2: Forward-Looking Statements

    ee Forward-Looking Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking informa

  3. Slide 3: Functional Cure Combination for Hepatitis B

    Functional Cure Combination for Hepatitis B Scientific consensus is that a functional cure is within reach, but will likely be achieved through a combination approach A functional cure will likely require the achievement of the below: 1. Drive down hepatitis B virus (HBV) DNA 2. Drive down immuno-su

  4. Slide 4: Overview of VBI's Tx HBV Phase 1b/2a Clinical Study

    ee Overview of VBI’s Tx HBV Phase 1b/2a Clinical Study VBI-2601 is an HBV immunotherapeutic candidate, building on the 3-antigen conformation of our prophylactic HBV vaccine (Sci-B-Vac), but reformulated to enhance T cell responses x Study designed and executed in partnership with Brii Biosciences B

  5. Slide 5: Interim Data Demonstrates Significant Restoration of Antibody and T Cell Responses

    Interim Data Demonstrates Significant Restoration of Antibody and T Cell Responses * Potent re-stimulation of T cell responses to HBV surface antigens (S, Pre-S1, Pre-S2) seen in 67% (n=6/9) and 78% (n=7/9) of evaluable patients in the low-dose VBI-2601 unadjuvanted and adjuvanted, respectively * Bo

  6. Slide 6: Lack of HBV-specific Immune Re-stimulation Correlates with Lack of HBsAg Seroconversion

    Lack of HBV-specific Immune Re-stimulation Correlates with Lack of HBsAg Seroconversion * 4-subjects showed no signs of antibody responses to S-antigen * 3 of those subjects showed no T cell response (T cell data not available for 4t* subject) VBI-2601 Unadjuvanted Data — Non-Responders suB023 suBs0

  7. Slide 7: VBI-2601 Data Summary & Next Steps

    OO VBI-2601 Data Summary & Next Steps Low-dose VBI-2601 data demonstrated : * VBI-2601 was well-tolerated with no safety signals observed * Potent restimulation of T cell responses to HBV surface antigens (S, pre-S1, pre-S2) in 67% and 78% of evaluable patients in the unadjuvanted and adjuvanted arm

  8. Slide 8: VBI Vaccines Inc. contact details

    VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com

VBI Vaccines — Corporate Update (November 2020) on 6ix